Mandatory universal drug plan, access to health care and health: Evidence from Canada

被引:12
作者
Wang, Chao [1 ]
Li, Qing [1 ]
Sweetman, Arthur [2 ,3 ]
Hurley, Jeremiah [2 ,3 ]
机构
[1] Capital Univ Econ & Business, Int Sch Econ & Management, Beijing 100070, Peoples R China
[2] McMaster Univ, Dept Econ, Hamilton, ON L8S 4M4, Canada
[3] McMaster Univ, Ctr Hlth Econ & Policy CHEPA, Hamilton, ON L8S 4K1, Canada
关键词
Universal drug insurance; Drug utilization; Health care utilization; Health status; Physician visits; MEDICARE-PART-D; VALUE-BASED INSURANCE; DIFFERENCE-IN-DIFFERENCES; INDEX MARK 3; PRESCRIPTION DRUGS; IMPACT; COST; COVERAGE; CONSEQUENCES; ELASTICITY;
D O I
10.1016/j.jhealeco.2015.08.004
中图分类号
F [经济];
学科分类号
02 ;
摘要
This paper examines the impacts of a mandatory, universal prescription drug insurance program on health care utilization and health outcomes in a public health care system with free physician and hospital services. Using the Canadian National Population Health Survey from 1994 to 2003 and implementing a difference-in-differences estimation strategy, we find that the mandatory program substantially increased drug coverage among the general population. The program also increased medication use and general practitioner visits but had little effect on specialist visits and hospitalization. Findings from quantile regressions suggest that there was a large improvement in the health status of less healthy individuals. Further analysis by pre-policy drug insurance status and the presence of chronic conditions reveals a marked increase in the probability of taking medication and visiting a general practitioner among the previously uninsured and those with a chronic condition. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 96
页数:17
相关论文
共 70 条
  • [21] The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
    Duggan, Mark
    Morton, Fiona Scott
    [J]. AMERICAN ECONOMIC REVIEW, 2010, 100 (01) : 590 - 607
  • [22] Federal/ Provincial/ Territorial Ministerial Task Force on the National Pharmaceuticals Strategy, 2006, NAT PHARM STRAT PROG
  • [23] Fendrick AM, 2006, AM J MANAG CARE, V12, P18
  • [24] Furlong W., 1999, Health Utilities Index (HUI): Algorithm for determining HUI mark 2 (HUI2)/HUI mark 3 (HUI3) health status classification levels, health states, health62 related quality of life utility scores and single-attribute utility score from 40-item interviewer administered health status questionnaires
  • [25] Gazette Officielle du Quebec, 1996, GAZETTE OFFICIELLE Q, V128, P3601
  • [26] In search of a corrected prescription drug elasticity estimate: A meta-regression approach
    Gemmill, Marin C.
    Costa-Font, Joan
    McGuire, Alistair
    [J]. HEALTH ECONOMICS, 2007, 16 (06) : 627 - 643
  • [27] Value-Based Insurance Plus Disease Management Increased Medication Use And Produced Savings
    Gibson, Teresa B.
    Mahoney, John
    Ranghell, Karlene
    Cherney, Becky J.
    McElwee, Newell
    [J]. HEALTH AFFAIRS, 2011, 30 (01) : 100 - 108
  • [28] Prescription drug cost sharing associations with medication and medical utilization and spending and health
    Goldman, Dana P.
    Joyce, Geoffrey F.
    Zheng, Yuhui
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (01): : 61 - 69
  • [29] Health Utilities Index Mark 3 - Evidence of construct validity for stroke and arthritis in a population health survey
    Grootendorst, P
    Feeny, D
    Furlong, W
    [J]. MEDICAL CARE, 2000, 38 (03) : 290 - 299
  • [30] Grootendorst Paul, 2002, Can J Clin Pharmacol, V9, P79